FDA Lanifibranor coverage for business development, investment, and market access teams
Inventiva has announced key leadership changes in anticipation of the upcoming Phase 3 data readout for Lanifibranor, which could significantly impact the market.
We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy
